← Back to all trials
Recruiting
NCT06701721
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 21
Sponsor: Therini Bio Pty Ltd
Location: Marsden Eye Specialists Parramatta New South Wales
Summary
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
Eligibility Criteria
Inclusion Criteria:
* Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
* 18 to 80 years of age (inclusive at the time of informed consent).
* Diagnosis of Diabetic Macular Edema (DME)
* Vision loss in the study eye
Exclusion Criteria:
* Be pregnant or breastfeeding
* Cataract surgery or any other previous ocular surgery in the study eye within 3 months before Screening
* Any other condition except for DME that could affect interpretation of study assessments
Source: ClinicalTrials.gov (NCT06701721). StuddyBuddy aggregates publicly available trial information.
